Cost Effective In-House Production Processes And Evaluation Of Cephalosporins And Metformin

The report deals with understanding the problems that have arisen in the Pharmaceutical industry and the classes of drugs which are suffering the brunt of Chinese influx in the Indian market. Since our thrust area itself has to deal with the problems being faced by the pharmaceutical industry and the lack of self- reliance when it comes to APIs, we first decided to go with official government data of the APIs being imported from China and work commenced from there. Based on government data, market share, consumption, pricing of drugs and import reports, we selected two drugs, one being an anti-bacterial drug which requires fermentation namely, cephalosporins and the other being a well-known anti-diabetic drug, Metformin. Currently, we are looking at the various technologies being used in producing the two drugs which were shortlisted and, we’ll be further finding out the loopholes in the system and fixing it or suggesting novel techniques to make the Indian Pharmaceutical industry a powerhouse. Both cephalosporins and metformin have been majorly imported from China due to several loopholes in producing them here in India and to add to it, the strategic pricing employed by the Chinese manufacturers gives them an edge over indigenous products. The manufacturing processes and regulations for both cephalosporins and metformin, need to undergo an overhaul in order to compete with giants like China and thus displace them from their position of number 1 in this field. Finding loopholes in the technology and regulatory factors, suggesting novel technologies or improvements within current processes and performing a detailed cost analysis.